Filing Details

Accession Number:
0001209191-22-024859
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-04-19 19:59:48
Reporting Period:
2022-04-18
Accepted Time:
2022-04-19 19:59:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1808865 Iteos Therapeutics Inc. ITOS Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1816196 Michel Detheux 321 Arsenal Street
Watertown MA 02472
Chief Executive Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-04-18 11,500 $4.23 37,763 No 4 M Direct
Common Stock Disposition 2022-04-18 11,467 $31.87 26,296 No 4 S Direct
Common Stock Disposition 2022-04-18 33 $32.64 26,263 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2022-04-18 11,500 $0.00 11,500 $4.23
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
144,464 2030-05-01 No 4 M Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Option (Right to Buy) $4.23 2030-05-01 185,000 185,000 Indirect
Expiration Date Amount Remaning Holdings Nature of Ownership
2030-05-01 185,000 185,000 Indirect
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.39 to $32.37, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  2. 25% of the shares subject to the stock option vested on May 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date.